Lipobon

Ezetimibe, the active ingredient in Lipobon, is a cholesterol absorption inhibitor presented as an oral tablet for oral use. It reduces elevated low‑density lipoprotein (LDL) cholesterol and is indicated for patients with primary hypercholesterolemia, including familial and homozygous forms.

GNH USA supplies Lipobon as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global logistics for regulated medicines. Lipobon meets EU marketing authorisation requirements and is manufactured under GMP conditions.

Ezetimibe lowers cholesterol by inhibiting intestinal absorption, and it is used in the management of several lipid disorders. - Hypercholesterolemia: reduces LDL‑cholesterol levels to help achieve target lipid goals. - Familial hypercholesterolemia: provides additional LDL‑cholesterol reduction when combined with statins in heterozygous patients. - Homozygous familial hypercholesterolemia: used as part of combination therapy to lower extremely high LDL‑cholesterol.

Like all medicines, ezetimibe may cause unwanted reactions, most of which are mild and reversible.

Common Side Effects: - Abdominal discomfort: mild stomach pain or cramping. - Diarrhea: loose stools occurring intermittently. - Fatigue: feeling unusually tired. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Myopathy: muscle pain or weakness, especially when combined with statins. - Rhabdomyolysis: severe muscle breakdown that can cause dark urine and kidney injury. - Severe allergic reaction: rash, itching, swelling, or difficulty breathing.

Before prescribing ezetimibe, clinicians should consider several safety aspects to minimise risk. - Liver function monitoring: check baseline ALT/AST and repeat periodically. - Concomitant statin therapy: assess risk of myopathy when used together. - Pregnancy and lactation: avoid use because safety has not been established. - Renal impairment: use with caution in severe kidney disease. - Drug interactions: review patient’s medication list for potential interactions. - Store at ambient temperature: keep below 25 °C in the original container, protected from moisture.

Ezetimibe can affect, or be affected by, other medicines; awareness of key interactions helps ensure safe use.

Major Interactions (Avoid): - Cyclosporine: co‑administration markedly increases ezetimibe plasma levels. - Antifungal azoles (ketoconazole, itraconazole): may raise ezetimibe concentrations. - Gemfibrozil: combined use raises risk of muscle toxicity.

Moderate Interactions (Monitor Closely): - Statins (especially high‑dose simvastatin): increased risk of myopathy; monitor CK. - Bile acid sequestrants: may reduce ezetimibe absorption; separate dosing by at least 1 hour. - Warfarin: occasional reports of altered INR; monitor coagulation parameters.